Laboratorios Farmaceuticos Rovi S.A
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more
Laboratorios Farmaceuticos Rovi S.A (LABFF) - Total Assets
Latest total assets as of September 2025: $922.07 Million USD
Based on the latest financial reports, Laboratorios Farmaceuticos Rovi S.A (LABFF) holds total assets worth $922.07 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Laboratorios Farmaceuticos Rovi S.A - Total Assets Trend (2004–2024)
This chart illustrates how Laboratorios Farmaceuticos Rovi S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Laboratorios Farmaceuticos Rovi S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Laboratorios Farmaceuticos Rovi S.A's total assets of $922.07 Million consist of 58.9% current assets and 41.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.3% |
| Accounts Receivable | $144.12 Million | 17.3% |
| Inventory | $329.95 Million | 39.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $33.95 Million | 4.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Laboratorios Farmaceuticos Rovi S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Laboratorios Farmaceuticos Rovi S.A's current assets represent 58.9% of total assets in 2024, a decrease from 68.5% in 2004.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2024, down from 6.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 39.7% of total assets.
Laboratorios Farmaceuticos Rovi S.A Competitors by Total Assets
Key competitors of Laboratorios Farmaceuticos Rovi S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Laboratorios Farmaceuticos Rovi S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Laboratorios Farmaceuticos Rovi S.A generates 0.92x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Laboratorios Farmaceuticos Rovi S.A generates $ 16.45 in net profit.
Laboratorios Farmaceuticos Rovi S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 2.50 | 2.97 |
| Quick Ratio | 1.32 | 0.94 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $373.77 Million | $ 332.34 Million | $ 241.69 Million |
Laboratorios Farmaceuticos Rovi S.A - Advanced Valuation Insights
This section examines the relationship between Laboratorios Farmaceuticos Rovi S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.75 |
| Latest Market Cap to Assets Ratio | 1.81 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | $832.02 Million |
| Market Capitalization | $1.51 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Laboratorios Farmaceuticos Rovi S.A's assets above their book value (1.81 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Laboratorios Farmaceuticos Rovi S.A's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Laboratorios Farmaceuticos Rovi S.A (2004–2024)
The table below shows the annual total assets of Laboratorios Farmaceuticos Rovi S.A from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $832.02 Million | +4.02% |
| 2023-12-31 | $799.88 Million | -8.97% |
| 2022-12-31 | $878.70 Million | +19.93% |
| 2021-12-31 | $732.68 Million | +27.55% |
| 2020-12-31 | $574.44 Million | +12.37% |
| 2019-12-31 | $511.21 Million | +26.95% |
| 2018-12-31 | $402.70 Million | +34.96% |
| 2017-12-31 | $298.38 Million | +3.66% |
| 2016-12-31 | $287.85 Million | +9.10% |
| 2015-12-31 | $263.85 Million | +0.97% |
| 2014-12-31 | $261.32 Million | +10.76% |
| 2013-12-31 | $235.92 Million | +6.10% |
| 2012-12-31 | $222.36 Million | -2.50% |
| 2011-12-31 | $228.07 Million | +7.13% |
| 2010-12-31 | $212.89 Million | +28.31% |
| 2009-12-31 | $165.91 Million | +22.08% |
| 2008-12-31 | $135.91 Million | +21.17% |
| 2007-12-31 | $112.16 Million | +47.50% |
| 2006-12-31 | $76.04 Million | -100.00% |
| 2005-12-31 | $8.15 Trillion | +103335.75% |
| 2004-12-31 | $7.88 Billion | -- |